Article
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jan 2020
Ascierto P A, Lewis K D, Di Giacomo A M, Demidov L, Mandalà M, Bondarenko I, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Simmons B, Ye C, Hooper G, Wongchenko M J, Goodman G R, Yan Y, Schadendorf D
Abstract excerpt
BACKGROUND: We conducted a retrospective exploratory analysis to evaluate the effects of baseline tumour immune infiltrate on disease-free survival (DFS) outcomes in patients with fully resected stage IIC-IIIC melanoma receiving adjuvant vemurafenib monotherapy or placebo in the BRIM8 study. PATIENTS AND METHODS: BRIM8 was a phase III, international, double-blind, randomised, placebo-controlled study. Eligible...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.